Zenas BioPharma (ZBIO) Income from Continuing Operations (2023 - 2026)

Zenas BioPharma's Income from Continuing Operations history runs 4 years deep, the most recent figure standing at 80987000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 141.23% year-over-year to 80987000.0; the TTM figure through Mar 2026 stood at 435844000.0 (down 161.47% YoY), while the FY2025 annual figure was 388430000.0, down 140.74% from the prior year.
• Income from Continuing Operations was 80987000.0 for Q1 2026 at Zenas BioPharma, up from 251135000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 35624000.0 in Q3 2023 to a low of 251135000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 56317181.82 across 4 years, with a median of 38606000.0 in 2024.
• Biggest YoY gain for Income from Continuing Operations was 20.77% in 2025; the steepest drop was 344.22% in 2025.
• A 4-year view of Income from Continuing Operations shows it stood at 24779000.0 in 2023, then tumbled by 128.15% to 56534000.0 in 2024, then sank by 344.22% to 251135000.0 in 2025, then soared by 67.75% to 80987000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 80987000.0 (Q1 2026), 251135000.0 (Q4 2025), and 51499000.0 (Q3 2025), per Business Quant data.